If you have been reading about Lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-07. Numbers and descriptions here follow the published literature rather than marketing material.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
=== Kulturgüter === Im Zuge der Aufhebung der Okresy als Gebietskörperschaften übernahm der Ústecký kraj Ende 2001 vom Okres Louny das Schloss Nový Hrad, das seit 1994 unter der Leitung des Regionalmuseums Louny zur touristischen Nutzung restauriert wird. Mit Beginn des Jahres 2012 wurde das Schloss in einen Zuschussbetrieb des Ústecký kraj überführt, der die Arbeiten in Eigenregie fortsetzt.
== Sehenswürdigkeiten == In Anbetracht der dichten Besiedlung bereits im frühen Mittelalter findet man in der Region eine hohe Anzahl historischer Stätten. Zu den bekanntesten gehören die romanische Rotunde auf dem sagenumwobenen Berg Říp, die gotische Kirche in Most (Brüx), das Barockschloss Duchcov, die Klöster Osek und Doksany, die Schlösser Ploskovice, Libochovice sowie die Altstädte von Úštěk, Roudnice nad Labem und der Bischofsstadt Leitmeritz. In der Festungsstadt Terezín gibt es eine Gedenkstätte für die Opfer des KZ Theresienstadt. Einige Dörfer im Bezirk Litoměřice sind denkmalgeschützt. Trotz ihrer hohen Industrialisierung bietet die Region eine schöne Landschaft. Dazu gehören die Böhmische Schweiz und das Böhmische Mittelgebirge mit der Porta Bohemica, die Felsenstadt Tiské stěny und viele andere. Sportbegeisterte besuchen die Rennbahnen Hippodrom, Autodrom und Golfplätze in Most. Die Region ist auch mit Radwanderwegen (cyklotrasa) gut erschlossen. Hinzu kommen vorzügliche Wintersportmöglichkeiten im Erzgebirge und Lausitzer Gebirge.
== Politik == Im November 2024 wurde Richard Brabec (ANO) zum Hejtman (Landeshauptmann) des Ústecký kraj gewählt. Zuvor war Jan Schiller (ebenfalls ANO) seit 2020 Hejtman. Zuvor war seit dem 20. November 2012 Oldřich Bubeníček (KSČM) Hejtman. Bubeníček war der erste Politiker der KSČM in der Tschechischen Republik, der nach 1990 in einem Kráj das Amt des Hejtman übernahm. Er regierte in einer Koalition aus seiner KSČM und den Sozialdemokraten (ČSSD), welche die Positionen im Rat des Kreises (rada kraje) besetzen. Er war der dritte Hejtman des Bezirks nach Jana Vaňhová (ČSSD), die von 2008 bis 2012 amtierte und Jiří Šulc (ODS), der von 2000 bis 2008 im Amt war. Der Rat des Kreises wird vom Regionalparlament (Zastupitelstvo kraje) gewählt. Bei den Wahlen zum Regionalparlament (Zastupitelstvo kraje) 2016 betrug die Wahlbeteiligung 28,94 Prozent. Das Regionalparlament hat 55 Sitze, von denen ANO als stärkste politische Kraft mit 23,24 % 20 erhielt. Die in diesem Bezirk traditionell starke KSČM, welche nach den Wahlen 2012 erstmals bei einer Regionalwahl in Tschechien stärkste Kraft wurde, erreichte mit 15,82 % nur noch das zweitstärkste Ergebnis und so 13 Sitze. Die ČSSD kam mit 11,9 % auf 10 Sitze, auf die ODS entfielen mit 8,54 % 7 Sitze. Die verbleibenden 5 Sitze erhielten SPO + SPD (6,07 %). Die übrigen Stimmen wurden für Parteien abgegeben, die an der Sperrklausel von 5 Prozent für den Einzug ins Parlament scheiterten.
Sources: de.wikipedia.org
=== Internationale Zusammenarbeit === Die internationale Zusammenarbeit bekräftigen zwei Euroregionen. Die Euroregion Elbe/Labe nimmt eine Fläche von 5400 km² ein auf der 1,4 Mio. Menschen leben. Zu ihr gehören 214 tschechische und 63 sächsische Gemeinden. Hierzu gehören Gebiete Nordböhmens, der Sächsischen Schweiz, ein Teil der sächsischen Oberelbe und des Osterzgebirges. Die Euroregion Erzgebirge/Krušnohoří bilden auf der tschechischen Seite 72 Gemeinden in den Bezirken Chomutov, Most, Louny und Teplice.
Sources: de.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.